PDE8A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL160472	0.51	7/20
SCHEMBL100704	1.00	3/20
SCHEMBL100957	1.00	3/20
SCHEMBL101130	1.00	3/20
SCHEMBL100239	0.93	3/20
SCHEMBL100852	0.93	3/20
SCHEMBL100878	0.93	3/20
SCHEMBL99932	0.91	3/20
SCHEMBL100716	0.91	3/20
SCHEMBL100171	0.90	3/20
SCHEMBL100224	0.89	3/20
SCHEMBL99882	0.88	3/20
SCHEMBL99921	0.88	3/20
SCHEMBL100723	0.88	3/20
SCHEMBL100771	0.88	3/20
SCHEMBL100095	0.87	3/20
SCHEMBL100102	0.87	3/20
SCHEMBL100222	0.87	3/20
SCHEMBL100844	0.87	3/20
SCHEMBL100702	0.87	3/20

Clinical trials — most relevant to PDE8A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?	PHASE4	COMPLETED
Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness	PHASE4	COMPLETED
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction	PHASE3	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)	PHASE1/PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism	PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	PHASE2	COMPLETED
A Trial of Metformin in Individuals With Fragile X Syndrome (Met)	PHASE2	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram	PHASE1	COMPLETED
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease	PHASE1	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients	PHASE1	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis	nan	NOT_YET_RECRUITING
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.	nan	UNKNOWN
Is Pentoxifylline Able to Improve Olfactory Sensitivity?	nan	COMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial	nan	COMPLETED
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load	nan	COMPLETED
Caffeine Efficacy in ADCY5-related Dyskinesia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDE8A binder may also engage these)

Protein	Name	Similarity
E9Q4S1	—	1.000	E9Q4S1 →
PDE8B	High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B	1.000	landscape →
O88502	—	1.000	O88502 →
O70628	—	0.996	O70628 →
H2QL32	—	0.993	H2QL32 →
PDE9A	High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A	0.992	landscape →
Q9H1H9	—	0.991	Q9H1H9 →
Q8QZV1	—	0.991	Q8QZV1 →
A2CEA7	—	0.991	A2CEA7 →
A1ZAJ2	—	0.991	A1ZAJ2 →
Q8I0P7	—	0.991	Q8I0P7 →
KDM5B	Lysine-specific demethylase 5B	0.991	landscape →
P30645	—	0.990	P30645 →
O18696	—	0.990	O18696 →
B4NBB0	—	0.990	B4NBB0 →
PDE4B	3',5'-cyclic-AMP phosphodiesterase 4B	0.990	landscape →
P14646	—	0.990	P14646 →
Q03603	—	0.990	Q03603 →
Q9SCX5	—	0.990	Q9SCX5 →
I1MGE5	—	0.990	I1MGE5 →
D3ZA12	—	0.989	D3ZA12 →
Q9D3R6	—	0.989	Q9D3R6 →
Q6NNF2	—	0.989	Q6NNF2 →
Q09639	—	0.989	Q09639 →
P15001	—	0.989	P15001 →
P40421	—	0.989	P40421 →
A3KFM7	—	0.989	A3KFM7 →
B0XDC4	—	0.989	B0XDC4 →
B3M383	—	0.989	B3M383 →
F4IDQ6	—	0.989	F4IDQ6 →